TTX-030 + budigalimab + mFOLFOX6

TTX-030 + budigalimab + mFOLFOX6 is a multi-drug experimental immuno-chemotherapy regimen under Phase 2 clinical evaluation for first-line treatment of metastatic pancreatic cancer. The regimen combines: - **TTX-030**: a first-in-class, anti-CD39 monoclonal antibody that inhibits extracellular adenosine generation in the tumor microenvironment, aiming to relieve immunosuppression and promote anti-tumor immune responses. - **Budigalimab**: an investigational anti-PD-1 monoclonal antibody immune checkpoint inhibitor. - **mFOLFOX6**: a modified FOLFOX6 chemotherapy regimen (oxaliplatin, leucovorin [folinic acid], and 5-fluorouracil) widely used to treat gastrointestinal malignancies, particularly colorectal and pancreatic cancers[1][2][5][6][7]. This regimen is administered intravenously and aims to synergize immune checkpoint blockade (by budigalimab), adenosine pathway inhibition (by TTX-030), and cytotoxic chemotherapy (by mFOLFOX6)[1][3][5][7].